|
CA2920368A1
|
|
Use of a cd6 binding partner and method based thereon
|
|
TN2013000151A1
|
|
Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
|
|
MX2014010456A
|
|
Recombinant antibodies having dual specificity for gangliosides and use thereof.
|
|
WO2013097834A1
|
|
Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3)
|
|
KR20130091346A
|
|
Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
|
|
TW201217000A
|
|
Vaccine compositions based on sticholysin encapsulated into liposomes
|
|
BR112012012025A2
|
|
interleukin-2 derived immunomodulatory polypeptide, fusion protein, pharmaceutical composition and uses of the polypeptide and fusion protein
|
|
TW201103559A
|
|
Anti sulfatides and anti sulfated proteoglycans antibodies and their use
|
|
WO2009152783A1
|
|
Inhibitors of the epidermal growth factor receptor (egfr) with cytostatic action and their uses in tumour therapy
|
|
EP2070547A1
|
|
A composition comprising humanized anti-egfr mab h-r3 antibody and type i inf for use in treating cancer
|
|
CU23652A1
|
|
HOMOGENOUS VACCINE COMPOSITION FOR THE TREATMENT OF CANCER AND ITS METHOD OF OBTAINING
|
|
WO2006119714A1
|
|
Method for the simulation of molecular binding with a flexible receptor using a novel scoring function
|
|
CN101061136A
|
|
Immunity therapeutic preparation with interleukin-2 neutralizing function
|
|
CN1809592A
|
|
Recombinant antibodies and fragments recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumours
|
|
MY144088A
|
|
Procedure for obtaining cell lines in protein-free media and cell line obtained by the method
|
|
CU23257A1
|
|
GANGLIOSID BASED VACCINE COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION
|
|
MXPA02010471A
|
|
Method of obtaining cell lines in a protein-free medium and cell lines thus obtained.
|
|
AR033123A1
|
|
RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS. ITS USE IN DIAGNOSIS AND TUMOR TREATMENT
|
|
MY129626A
|
|
Preparations that potentiate immunogenicity in low immunogenic antigens
|
|
MY141122A
|
|
Vaccine composition containing transforming growth factor alpha (tgf[alpha]). it use in malignant diseases therapy
|
